News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
714,007 Results
Type
Article (42324)
Company Profile (436)
Press Release (671247)
Multimedia
Podcasts (77)
Webinars (13)
Section
Business (208754)
Career Advice (2022)
Deals (36008)
Drug Delivery (104)
Drug Development (83641)
Employer Resources (173)
FDA (16435)
Job Trends (15094)
News (352878)
Policy (33087)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (8)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (5)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (8)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (2)
Academia (2643)
Accelerated approval (6)
Adcomms (24)
Allergies (84)
Alliances (50953)
ALS (95)
Alzheimer's disease (1426)
Antibody-drug conjugate (ADC) (137)
Approvals (16422)
Artificial intelligence (262)
Autoimmune disease (25)
Automation (16)
Bankruptcy (372)
Best Places to Work (11841)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (330)
Bladder cancer (71)
Brain cancer (26)
Breast cancer (280)
Cancer (2229)
Cardiovascular disease (182)
Career advice (1689)
Career pathing (30)
CAR-T (152)
Cell therapy (429)
Cervical cancer (19)
Clinical research (67772)
Collaboration (860)
Compensation (527)
Complete response letters (24)
COVID-19 (2645)
CRISPR (42)
C-suite (243)
Cystic fibrosis (105)
Data (2129)
Decentralized trials (2)
Denatured (28)
Depression (49)
Diabetes (268)
Diagnostics (6417)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (127)
Drug pricing (107)
Drug shortages (26)
Duchenne muscular dystrophy (99)
Earnings (87690)
Editorial (39)
Employer branding (21)
Employer resources (147)
Events (115689)
Executive appointments (725)
FDA (17668)
Featured Employer (54)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (778)
Gene editing (109)
Generative AI (20)
Gene therapy (314)
GLP-1 (743)
Government (4500)
Grass and pollen (4)
Guidances (52)
Healthcare (19149)
Huntington's disease (24)
IgA nephropathy (27)
Immunology and inflammation (127)
Indications (29)
Infectious disease (2790)
Inflammatory bowel disease (141)
Inflation Reduction Act (11)
Influenza (52)
Intellectual property (94)
Interviews (311)
IPO (16781)
IRA (43)
Job creations (3700)
Job search strategy (1434)
Kidney cancer (10)
Labor market (38)
Layoffs (492)
Leadership (17)
Legal (7986)
Liver cancer (74)
Lung cancer (318)
Lymphoma (149)
Machine learning (6)
Management (58)
Manufacturing (305)
MASH (68)
Medical device (13515)
Medtech (13520)
Mergers & acquisitions (19750)
Metabolic disorders (705)
Multiple sclerosis (79)
NASH (19)
Neurodegenerative disease (99)
Neuropsychiatric disorders (33)
Neuroscience (1982)
NextGen: Class of 2025 (6755)
Non-profit (4549)
Northern California (2631)
Now hiring (39)
Obesity (381)
Opinion (224)
Ovarian cancer (75)
Pain (85)
Pancreatic cancer (82)
Parkinson's disease (153)
Partnered (21)
Patents (230)
Patient recruitment (106)
Peanut (47)
People (58644)
Pharmaceutical (86)
Pharmacy benefit managers (19)
Phase I (21318)
Phase II (29892)
Phase III (22102)
Pipeline (1164)
Policy (143)
Postmarket research (2601)
Preclinical (9088)
Press Release (67)
Prostate cancer (103)
Psychedelics (37)
Radiopharmaceuticals (262)
Rare diseases (400)
Real estate (6014)
Recruiting (66)
Regulatory (22710)
Reports (46)
Research institute (2416)
Resumes & cover letters (352)
Rett syndrome (4)
RNA editing (4)
RSV (42)
Schizophrenia (74)
Series A (138)
Series B (89)
Service/supplier (11)
Sickle cell disease (57)
Southern California (2271)
Special edition (17)
Spinal muscular atrophy (152)
Sponsored (30)
Startups (3763)
State (2)
Stomach cancer (14)
Supply chain (68)
Tariffs (33)
The Weekly (47)
United States (23065)
Vaccines (697)
Venture capitalists (43)
Weight loss (252)
Women's health (37)
Worklife (16)
Date
Today (41)
Last 7 days (659)
Last 30 days (2420)
Last 365 days (33700)
2025 (10135)
2024 (36310)
2023 (41025)
2022 (52294)
2021 (56776)
2020 (54928)
2019 (47425)
2018 (35701)
2017 (33034)
2016 (32355)
2015 (38402)
2014 (32194)
2013 (27114)
2012 (29231)
2011 (29873)
2010 (28000)
Location
Africa (736)
Alabama (57)
Alaska (7)
Arizona (238)
Arkansas (14)
Asia (39239)
Australia (6530)
California (6068)
Canada (1983)
China (516)
Colorado (267)
Connecticut (278)
Delaware (142)
Europe (85739)
Florida (882)
Georgia (203)
Idaho (57)
Illinois (539)
India (25)
Indiana (309)
Iowa (12)
Japan (159)
Kansas (105)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (891)
Massachusetts (4606)
Michigan (218)
Minnesota (390)
Mississippi (2)
Missouri (82)
Montana (29)
Nebraska (25)
Nevada (60)
New Hampshire (66)
New Jersey (1714)
New Mexico (30)
New York (1711)
North Carolina (1018)
North Dakota (7)
Northern California (2631)
Ohio (202)
Oklahoma (14)
Oregon (38)
Pennsylvania (1352)
Puerto Rico (11)
Rhode Island (33)
South America (1110)
South Carolina (22)
South Dakota (1)
Southern California (2271)
Tennessee (101)
Texas (899)
Utah (180)
Virginia (145)
Washington D.C. (63)
Washington State (566)
West Virginia (3)
Wisconsin (53)
714,007 Results for "ascend therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Vivex Biologics, Inc. Provides Enrollment Update for its ASCEND Study Examining Whether Supplementing Discs with VIA Disc NP™ Reduces Pain and/or Improves Function in Patients with Symptomatic Disc Degeneration
April 9, 2025
·
2 min read
Press Releases
AtaCor Medical Enrolls First Patients in its ASCEND EV Clinical Study
March 24, 2025
·
3 min read
Press Releases
Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease
March 4, 2025
·
8 min read
Biotech Beach
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
Biora Therapeutics, Inc today announced completion of dosing for the multiple-ascending dose cohorts for its clinical study of BT-600.
April 30, 2024
·
7 min read
Press Releases
Ascend Advanced Therapies Appoints John Chiminski as Chair and Karen Flynn as Independent Director
March 5, 2025
·
3 min read
Press Releases
Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis
April 9, 2025
·
6 min read
Press Releases
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
March 25, 2025
·
7 min read
Drug Development
Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease
Voyager Therapeutics, Inc. today announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigational anti-tau antibody developed to inhibit the spread of pathological tau in Alzheimer’s disease.
May 16, 2024
·
6 min read
Press Releases
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025
March 11, 2025
·
9 min read
Press Releases
Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency
January 7, 2025
·
8 min read
1 of 71,401
Next
